On Monday, Shares of Allianzgi Convertible & Income Fund (NYSE:NCV), lost -3.04% to $6.06.
Allianz GI Convertible & Income Fund and AllianzGI Convertible & Income Fund II, declared dividend changes this month. The dividend reductions were made in large part in recognition of changing market dynamics and to better align the dividend rates of the two Funds with their current and projected level of earnings.
The dividends will be payable on October 1, 2015 to shareholders of record on September 11, 2015, with an ex-dividend date of September 9, 2015.
The Funds are closed-end administration investment companies. The Funds’ investment objective is to provide total return through a combination of capital appreciation and current income. There can be no assurance that the Funds will achieve their stated objectives.
AllianzGI Convertible & Income Fund is a closed-end fund. The Fund investment objective is to provide total return through a combination of capital appreciation and high current income. The Funds attempt to achieve this objective by investing in a portfolio of convertible securities and non-convertible income-producing securities.
Shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), declined -4.27% to $18.18, during its last trading session.
Momenta Pharmaceuticals, declared that its presentation at the Morgan Stanley Global Healthcare Conference will be webcast on Friday, September 18, 2015 at 1:00 p.m. ET.
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune diseases.
At the end of Monday’s trade, Shares of Tripadvisor Inc (NASDAQ:TRIP), gained 1.30% to $67.79.
TripAdvisor, declared the launch of a new competition to uncover the best travel discoveries TripAdvisor users have made through the site.
The contest, entitled My TripAdvisor Discovery, will challenge members of the world’s largest travel community to submit a video that details in one minute or less a great discovery they have made while using TripAdvisor.
“No one knows travel better than the millions of TripAdvisor members who share their experiences on our site every day. Now, in addition to sharing their valuable reviews, they have a chance to highlight the best travel find or gem they discovered through the site, whether it’s a rustic little restaurant, a great hotel deal or an invaluable tip from the Forums,” said Barbara Messing, chief marketing officer for TripAdvisor.
TripAdvisor, Inc. operates as an online travel company. The company operates through two segments, Hotel and Other. Its travel research platform aggregates reviews and opinions about accommodations, destinations, activities and attractions, and restaurants that enable consumers to plan and book hotels, vacation rentals, flights, activities and attractions, and restaurants.
Finally, Array Biopharma Inc (NASDAQ:ARRY), ended its last trade with -0.17% loss, and closed at $5.87.
Array BioPharma, declared presentations on encorafenib and binimetinib at the 2015 European Cancer Congress (ECC), which will be held September 25 - 29, 2015 in Vienna, Austria. These products are presently advancing in a total of three pivotal trials, with top-line results predictable over the next year from the NEMO (binimetinib monotherapy in NRAS mutant melanoma) and COLUMBUS (binimetinib and encorafenib in BRAF mutant melanoma) Phase 3 trials.
Ron Squarer, Chief Executive Officer of Array, noted, “We are encouraged to see two ECC abstracts reporting clinical data from binimetinib and encorafenib. Importantly, the LOGIC2 presentation at ECC will provide a further opportunity to demonstrate the safety and clinical activity profile of this combination in a larger, independent data set.”
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
